{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T19:57:15Z","timestamp":1760731035852,"version":"3.37.3"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Soluble amyloid \u03b2 oligomers (A\u03b2Os) are widely recognized neurotoxins that trigger aberrant signaling in specific subsets of neurons, leading to accumulated neuronal damage and memory disorders in Alzheimer\u2019s disease (AD). One of the profound downstream consequences of A\u03b2O-triggered events is dysregulation of cytosolic calcium concentration ([Ca<jats:sup>2+<\/jats:sup>]<jats:sub>i<\/jats:sub>), which has been implicated in synaptic failure, cytoskeletal abnormalities, and eventually neuronal death. We have developed an <jats:italic>in vitro<\/jats:italic>\/<jats:italic>in vivo<\/jats:italic> drug screening assay to evaluate putative A\u03b2O-blocking candidates by measuring A\u03b2O-induced real-time changes in [Ca<jats:sup>2+<\/jats:sup>]<jats:sub>i<\/jats:sub>. Our screening assay demonstrated that the anti-A\u03b2O monoclonal antibody ACU3B3 exhibits potent blocking capability against a broad size range of A\u03b2Os. We showed that picomolar concentrations of A\u03b2Os were capable of increasing [Ca<jats:sup>2+<\/jats:sup>]<jats:sub>i<\/jats:sub> in primary neuronal cultures, an effect prevented by ACU3B3. Topical application of 5\u2009nM A\u03b2Os onto exposed cortical surfaces also elicited significant calcium elevations <jats:italic>in vivo<\/jats:italic>, which was completely abolished by pre-treatment of the brain with 1 ng\/mL (6.67 pM) ACU3B3. Our results provide strong support for the utility of this functional screening assay in identifying and confirming the efficacy of A\u03b2O-blocking drug candidates such as the human homolog of ACU3B3, which may emerge as the first experimental AD therapeutic to validate the amyloid oligomer hypothesis.<\/jats:p>","DOI":"10.1038\/s41598-018-22979-2","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T15:12:55Z","timestamp":1520608375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["An acute functional screen identifies an effective antibody targeting amyloid-\u03b2 oligomers based on calcium imaging"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2399-8083","authenticated-orcid":false,"given":"Xueying","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenia V.","family":"Kastanenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Arbel-Ornath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Commins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kuzuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda J.","family":"Lariviere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant A.","family":"Krafft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"Hefti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasna","family":"Jerecic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Bacskai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"22979_CR1","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America 95, 6448\u20136453 (1998).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"22979_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1385\/JMN:20:3:305","volume":"20","author":"L Chang","year":"2003","unstructured":"Chang, L., Bakhos, L., Wang, Z., Venton, D. L. & Klein, W. L. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer\u2019s disease drug candidate screening. J Mol Neurosci 20, 305\u2013313, https:\/\/doi.org\/10.1385\/JMN:20:3:305 (2003).","journal-title":"J Mol Neurosci"},{"key":"22979_CR3","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.1073\/pnas.1834302100","volume":"100","author":"Y Gong","year":"2003","unstructured":"Gong, Y. et al. Alzheimer\u2019s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America 100, 10417\u201310422, https:\/\/doi.org\/10.1073\/pnas.1834302100 (2003).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"22979_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1341","volume":"2","author":"DB Freir","year":"2011","unstructured":"Freir, D. B. et al. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun 2, 336, https:\/\/doi.org\/10.1038\/ncomms1341 (2011).","journal-title":"Nat Commun"},{"key":"22979_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ana.22052","volume":"68","author":"S Gandy","year":"2010","unstructured":"Gandy, S. et al. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol 68, 220\u2013230, https:\/\/doi.org\/10.1002\/ana.22052 (2010).","journal-title":"Ann Neurol"},{"key":"22979_CR6","doi-asserted-by":"publisher","first-page":"10191","DOI":"10.1523\/JNEUROSCI.3432-04.2004","volume":"24","author":"PN Lacor","year":"2004","unstructured":"Lacor, P. N. et al. Synaptic targeting by Alzheimer\u2019s-related amyloid beta oligomers. The Journal of neuroscience: the official journal of the Society for Neuroscience 24, 10191\u201310200, https:\/\/doi.org\/10.1523\/JNEUROSCI.3432-04.2004 (2004).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR7","doi-asserted-by":"publisher","first-page":"9090","DOI":"10.1523\/JNEUROSCI.1357-09.2009","volume":"29","author":"X Wang","year":"2009","unstructured":"Wang, X. et al. Impaired balance of mitochondrial fission and fusion in Alzheimer\u2019s disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 29, 9090\u20139103, https:\/\/doi.org\/10.1523\/JNEUROSCI.1357-09.2009 (2009).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR8","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1073\/pnas.0409336102","volume":"102","author":"DG Georganopoulou","year":"2005","unstructured":"Georganopoulou, D. G. et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer\u2019s disease. Proceedings of the National Academy of Sciences of the United States of America 102, 2273\u20132276, https:\/\/doi.org\/10.1073\/pnas.0409336102 (2005).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"22979_CR9","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage, M. J. et al. A sensitive abeta oligomer assay discriminates Alzheimer\u2019s and aged control cerebrospinal fluid. The Journal of neuroscience: the official journal of the Society for Neuroscience 34, 2884\u20132897, https:\/\/doi.org\/10.1523\/JNEUROSCI.1675-13.2014 (2014).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-015-0100-y","volume":"7","author":"T Yang","year":"2015","unstructured":"Yang, T. et al. A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. Alzheimers Res Ther 7, 14, https:\/\/doi.org\/10.1186\/s13195-015-0100-y (2015).","journal-title":"Alzheimers Res Ther"},{"key":"22979_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe, D. J. Alzheimer\u2019s disease is a synaptic failure. Science 298, 789\u2013791, https:\/\/doi.org\/10.1126\/science.1074069 (2002).","journal-title":"Science"},{"key":"22979_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8, 595\u2013608, https:\/\/doi.org\/10.15252\/emmm.201606210 (2016).","journal-title":"EMBO Mol Med"},{"key":"22979_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572\u2013580, https:\/\/doi.org\/10.1002\/ana.410300410 (1991).","journal-title":"Ann Neurol"},{"key":"22979_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0166-2236(00)01749-5","volume":"24","author":"WL Klein","year":"2001","unstructured":"Klein, W. L., Krafft, G. A. & Finch, C. E. Targeting small Abeta oligomers: the solution to an Alzheimer\u2019s disease conundrum? Trends Neurosci 24, 219\u2013224 (2001).","journal-title":"Trends Neurosci"},{"key":"22979_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","volume":"6","author":"U Sengupta","year":"2016","unstructured":"Sengupta, U., Nilson, A. N. & Kayed, R. The Role of Amyloid-beta Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine 6, 42\u201349, https:\/\/doi.org\/10.1016\/j.ebiom.2016.03.035 (2016).","journal-title":"EBioMedicine"},{"key":"22979_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","volume":"129","author":"KL Viola","year":"2015","unstructured":"Viola, K. L. & Klein, W. L. Amyloid beta oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol 129, 183\u2013206, https:\/\/doi.org\/10.1007\/s00401-015-1386-3 (2015).","journal-title":"Acta Neuropathol"},{"key":"22979_CR17","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1073\/pnas.0436286100","volume":"100","author":"F Bard","year":"2003","unstructured":"Bard, F. et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer\u2019s disease-like neuropathology. Proceedings of the National Academy of Sciences of the United States of America 100, 2023\u20132028, https:\/\/doi.org\/10.1073\/pnas.0436286100 (2003).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"22979_CR18","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard, F. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916\u2013919, https:\/\/doi.org\/10.1038\/78682 (2000).","journal-title":"Nat Med"},{"key":"22979_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart, J. C. et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer\u2019s disease model. Nat Neurosci 5, 452\u2013457, https:\/\/doi.org\/10.1038\/nn842 (2002).","journal-title":"Nat Neurosci"},{"key":"22979_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.bcp.2013.12.020","volume":"88","author":"T Wisniewski","year":"2014","unstructured":"Wisniewski, T. & Goni, F. Immunotherapy for Alzheimer\u2019s disease. Biochem Pharmacol 88, 499\u2013507, https:\/\/doi.org\/10.1016\/j.bcp.2013.12.020 (2014).","journal-title":"Biochem Pharmacol"},{"key":"22979_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk, D. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173\u2013177, https:\/\/doi.org\/10.1038\/22124 (1999).","journal-title":"Nature"},{"key":"22979_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/alzrt272","volume":"6","author":"WF Goure","year":"2014","unstructured":"Goure, W. F., Krafft, G. A., Jerecic, J. & Hefti, F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer\u2019s disease immunotherapeutics. Alzheimers Res Ther 6, 42, https:\/\/doi.org\/10.1186\/alzrt272 (2014).","journal-title":"Alzheimers Res Ther"},{"key":"22979_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.1994.tb44398.x","volume":"747","author":"ZS Khachaturian","year":"1994","unstructured":"Khachaturian, Z. S. Calcium hypothesis of Alzheimer\u2019s disease and brain aging. Ann N Y Acad Sci 747, 1\u201311 (1994).","journal-title":"Ann N Y Acad Sci"},{"key":"22979_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1749-6632.1994.tb44424.x","volume":"747","author":"JF Disterhoft","year":"1994","unstructured":"Disterhoft, J. F., Moyer, J. R. Jr & Thompson, L. T. The calcium rationale in aging and Alzheimer\u2019s disease. Evidence from an animal model of normal aging. Ann N Y Acad Sci 747, 382\u2013406 (1994).","journal-title":"Ann N Y Acad Sci"},{"key":"22979_CR25","doi-asserted-by":"publisher","unstructured":"Alzheimer\u2019s Association Calcium Hypothesis, W. Calcium Hypothesis of Alzheimer\u2019s disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis. Alzheimers Dement 13, 178\u2013182 e117 https:\/\/doi.org\/10.1016\/j.jalz.2016.12.006 (2017).","DOI":"10.1016\/j.jalz.2016.12.006"},{"key":"22979_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.neuron.2007.06.014","volume":"55","author":"KD Micheva","year":"2007","unstructured":"Micheva, K. D. & Smith, S. J. Array tomography: a new tool for imaging the molecular architecture and ultrastructure of neural circuits. Neuron 55, 25\u201336, https:\/\/doi.org\/10.1016\/j.neuron.2007.06.014 (2007).","journal-title":"Neuron"},{"key":"22979_CR27","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1073\/pnas.0811698106","volume":"106","author":"RM Koffie","year":"2009","unstructured":"Koffie, R. M. et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proceedings of the National Academy of Sciences of the United States of America 106, 4012\u20134017, https:\/\/doi.org\/10.1073\/pnas.0811698106 (2009).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"22979_CR28","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1074\/jbc.M109.057182","volume":"285","author":"WQ Zhao","year":"2010","unstructured":"Zhao, W. Q. et al. Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. J Biol Chem 285, 7619\u20137632, https:\/\/doi.org\/10.1074\/jbc.M109.057182 (2010).","journal-title":"J Biol Chem"},{"key":"22979_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.neuropharm.2011.01.051","volume":"60","author":"G Rammes","year":"2011","unstructured":"Rammes, G., Hasenjager, A., Sroka-Saidi, K., Deussing, J. M. & Parsons, C. G. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60, 982\u2013990, https:\/\/doi.org\/10.1016\/j.neuropharm.2011.01.051 (2011).","journal-title":"Neuropharmacology"},{"key":"22979_CR30","doi-asserted-by":"publisher","first-page":"32046","DOI":"10.1074\/jbc.M201750200","volume":"277","author":"KN Dahlgren","year":"2002","unstructured":"Dahlgren, K. N. et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277, 32046\u201332053, https:\/\/doi.org\/10.1074\/jbc.M201750200 (2002).","journal-title":"J Biol Chem"},{"key":"22979_CR31","doi-asserted-by":"publisher","first-page":"11612","DOI":"10.1074\/jbc.M210207200","volume":"278","author":"WB Stine Jr","year":"2003","unstructured":"Stine, W. B. Jr, Dahlgren, K. N., Krafft, G. A. & LaDu, M. J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278, 11612\u201311622, https:\/\/doi.org\/10.1074\/jbc.M210207200 (2003).","journal-title":"J Biol Chem"},{"key":"22979_CR32","doi-asserted-by":"publisher","first-page":"15157","DOI":"10.1021\/bi061850f","volume":"45","author":"RW Hepler","year":"2006","unstructured":"Hepler, R. W. et al. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 45, 15157\u201315167, https:\/\/doi.org\/10.1021\/bi061850f (2006).","journal-title":"Biochemistry"},{"key":"22979_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-60761-744-0_2","volume":"670","author":"WB Stine","year":"2011","unstructured":"Stine, W. B., Jungbauer, L., Yu, C. & LaDu, M. J. Preparing synthetic Abeta in different aggregation states. Methods in molecular biology 670, 13\u201332, https:\/\/doi.org\/10.1007\/978-1-60761-744-0_2 (2011).","journal-title":"Methods in molecular biology"},{"key":"22979_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neurobiolaging.2008.04.003","volume":"31","author":"PJ Shughrue","year":"2010","unstructured":"Shughrue, P. J. et al. Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiology of aging 31, 189\u2013202, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2008.04.003 (2010).","journal-title":"Neurobiology of aging"},{"key":"22979_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neuron.2008.06.008","volume":"59","author":"KV Kuchibhotla","year":"2008","unstructured":"Kuchibhotla, K. V. et al. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59, 214\u2013225, https:\/\/doi.org\/10.1016\/j.neuron.2008.06.008 (2008).","journal-title":"Neuron"},{"key":"22979_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13024-017-0169-9","volume":"12","author":"M Arbel-Ornath","year":"2017","unstructured":"Arbel-Ornath, M. et al. Soluble oligomeric amyloid-beta induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Mol Neurodegener 12, 27, https:\/\/doi.org\/10.1186\/s13024-017-0169-9 (2017).","journal-title":"Mol Neurodegener"},{"key":"22979_CR37","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/brain\/aws127","volume":"135","author":"RM Koffie","year":"2012","unstructured":"Koffie, R. M. et al. Apolipoprotein E4 effects in Alzheimer\u2019s disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain: a journal of neurology 135, 2155\u20132168, https:\/\/doi.org\/10.1093\/brain\/aws127 (2012).","journal-title":"Brain: a journal of neurology"},{"key":"22979_CR38","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/S0024-3205(01)01232-2","volume":"69","author":"WE Klunk","year":"2001","unstructured":"Klunk, W. E. et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 69, 1471\u20131484 (2001).","journal-title":"Life Sci"},{"key":"22979_CR39","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.expneurol.2009.09.001","volume":"223","author":"RC Gaspar","year":"2010","unstructured":"Gaspar, R. C. et al. Oligomers of beta-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model. Exp Neurol 223, 394\u2013400, https:\/\/doi.org\/10.1016\/j.expneurol.2009.09.001 (2010).","journal-title":"Exp Neurol"},{"key":"22979_CR40","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/brain\/awt062","volume":"136","author":"SE Lesne","year":"2013","unstructured":"Lesne, S. E. et al. Brain amyloid-beta oligomers in ageing and Alzheimer\u2019s disease. Brain: a journal of neurology 136, 1383\u20131398, https:\/\/doi.org\/10.1093\/brain\/awt062 (2013).","journal-title":"Brain: a journal of neurology"},{"issue":"825","key":"22979_CR41","doi-asserted-by":"publisher","first-page":"e821","DOI":"10.1016\/j.neurobiolaging.2011.05.003","volume":"33","author":"F Bao","year":"2012","unstructured":"Bao, F. et al. Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiology of aging 33(825), e821\u2013813, https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.05.003 (2012).","journal-title":"Neurobiology of aging"},{"key":"22979_CR42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/archneurol.2008.565","volume":"66","author":"W Xia","year":"2009","unstructured":"Xia, W. et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66, 190\u2013199, https:\/\/doi.org\/10.1001\/archneurol.2008.565 (2009).","journal-title":"Arch Neurol"},{"key":"22979_CR43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky, S. T. & Scheff, S. W. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol 27, 457\u2013464, https:\/\/doi.org\/10.1002\/ana.410270502 (1990).","journal-title":"Ann Neurol"},{"key":"22979_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/WNL.56.1.127","volume":"56","author":"E Masliah","year":"2001","unstructured":"Masliah, E. et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease. Neurology 56, 127\u2013129 (2001).","journal-title":"Neurology"},{"key":"22979_CR45","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/00005072-199708000-00011","volume":"56","author":"CI Sze","year":"1997","unstructured":"Sze, C. I. et al. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. Journal of neuropathology and experimental neurology 56, 933\u2013944 (1997).","journal-title":"Journal of neuropathology and experimental neurology"},{"key":"22979_CR46","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1212\/01.WNL.0000140626.48118.0A","volume":"63","author":"P Coleman","year":"2004","unstructured":"Coleman, P., Federoff, H. & Kurlan, R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 63, 1155\u20131162 (2004).","journal-title":"Neurology"},{"key":"22979_CR47","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","volume":"27","author":"PN Lacor","year":"2007","unstructured":"Lacor, P. N. et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer\u2019s disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 27, 796\u2013807, https:\/\/doi.org\/10.1523\/JNEUROSCI.3501-06.2007 (2007).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/nn.2476","volume":"13","author":"W Wei","year":"2010","unstructured":"Wei, W. et al. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci 13, 190\u2013196, https:\/\/doi.org\/10.1038\/nn.2476 (2010).","journal-title":"Nat Neurosci"},{"key":"22979_CR49","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nature07761","volume":"457","author":"J Lauren","year":"2009","unstructured":"Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. & Strittmatter, S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128\u20131132, https:\/\/doi.org\/10.1038\/nature07761 (2009).","journal-title":"Nature"},{"key":"22979_CR50","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1096\/fj.01-0987fje","volume":"17","author":"HJ Kim","year":"2003","unstructured":"Kim, H. J. et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 17, 118\u2013120, https:\/\/doi.org\/10.1096\/fj.01-0987fje (2003).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"22979_CR51","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1523\/JNEUROSCI.4970-06.2007","volume":"27","author":"GM Shankar","year":"2007","unstructured":"Shankar, G. M. et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. The Journal of neuroscience: the official journal of the Society for Neuroscience 27, 2866\u20132875, https:\/\/doi.org\/10.1523\/JNEUROSCI.4970-06.2007 (2007).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR52","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/nn.3178","volume":"15","author":"JW Um","year":"2012","unstructured":"Um, J. W. et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15, 1227\u20131235, https:\/\/doi.org\/10.1038\/nn.3178 (2012).","journal-title":"Nat Neurosci"},{"key":"22979_CR53","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/j.1474-9726.2008.00434.x","volume":"7","author":"LC Reese","year":"2008","unstructured":"Reese, L. C., Zhang, W., Dineley, K. T., Kayed, R. & Taglialatela, G. Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell 7, 824\u2013835, https:\/\/doi.org\/10.1111\/j.1474-9726.2008.00434.x (2008).","journal-title":"Aging Cell"},{"key":"22979_CR54","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/nn.2583","volume":"13","author":"JJ Palop","year":"2010","unstructured":"Palop, J. J. & Mucke, L. Amyloid-beta-induced neuronal dysfunction in Alzheimer\u2019s disease: from synapses toward neural networks. Nat Neurosci 13, 812\u2013818, https:\/\/doi.org\/10.1038\/nn.2583 (2010).","journal-title":"Nat Neurosci"},{"key":"22979_CR55","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh, D. M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535\u2013539, https:\/\/doi.org\/10.1038\/416535a (2002).","journal-title":"Nature"},{"key":"22979_CR56","doi-asserted-by":"publisher","first-page":"12893","DOI":"10.1523\/JNEUROSCI.1201-14.2014","volume":"34","author":"C Ripoli","year":"2014","unstructured":"Ripoli, C. et al. Intracellular accumulation of amyloid-beta (Abeta) protein plays a major role in Abeta-induced alterations of glutamatergic synaptic transmission and plasticity. The Journal of neuroscience: the official journal of the Society for Neuroscience 34, 12893\u201312903, https:\/\/doi.org\/10.1523\/JNEUROSCI.1201-14.2014 (2014).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR57","doi-asserted-by":"publisher","first-page":"11938","DOI":"10.1523\/JNEUROSCI.2357-10.2010","volume":"30","author":"H Zempel","year":"2010","unstructured":"Zempel, H., Thies, E., Mandelkow, E. & Mandelkow, E. M. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. The Journal of neuroscience: the official journal of the Society for Neuroscience 30, 11938\u201311950, https:\/\/doi.org\/10.1523\/JNEUROSCI.2357-10.2010 (2010).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR58","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/neu.480260305","volume":"26","author":"JR Brorson","year":"1995","unstructured":"Brorson, J. R. et al. The Ca2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. J Neurobiol 26, 325\u2013338, https:\/\/doi.org\/10.1002\/neu.480260305 (1995).","journal-title":"J Neurobiol"},{"key":"22979_CR59","doi-asserted-by":"publisher","first-page":"12549","DOI":"10.1523\/JNEUROSCI.2080-16.2016","volume":"36","author":"KV Kastanenka","year":"2016","unstructured":"Kastanenka, K. V. et al. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. The Journal of neuroscience: the official journal of the Society for Neuroscience 36, 12549\u201312558, https:\/\/doi.org\/10.1523\/JNEUROSCI.2080-16.2016 (2016).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR60","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12035-014-8994-0","volume":"53","author":"M Xia","year":"2016","unstructured":"Xia, M., Cheng, X., Yi, R., Gao, D. & Xiong, J. The Binding Receptors of Abeta: an Alternative Therapeutic Target for Alzheimer\u2019s Disease. Mol Neurobiol 53, 455\u2013471, https:\/\/doi.org\/10.1007\/s12035-014-8994-0 (2016).","journal-title":"Mol Neurobiol"},{"key":"22979_CR61","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1091\/mbc.E14-12-1612","volume":"26","author":"KJ Gan","year":"2015","unstructured":"Gan, K. J. & Silverman, M. A. Dendritic and axonal mechanisms of Ca2+ elevation impair BDNF transport in Abeta oligomer-treated hippocampal neurons. Mol Biol Cell 26, 1058\u20131071, https:\/\/doi.org\/10.1091\/mbc.E14-12-1612 (2015).","journal-title":"Mol Biol Cell"},{"key":"22979_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1750-1326-9-21","volume":"9","author":"D Del Prete","year":"2014","unstructured":"Del Prete, D., Checler, F. & Chami, M. Ryanodine receptors: physiological function and deregulation in Alzheimer disease. Mol Neurodegener 9, 21, https:\/\/doi.org\/10.1186\/1750-1326-9-21 (2014).","journal-title":"Mol Neurodegener"},{"key":"22979_CR63","doi-asserted-by":"publisher","first-page":"e52056","DOI":"10.1371\/journal.pone.0052056","volume":"7","author":"S Chakroborty","year":"2012","unstructured":"Chakroborty, S. et al. Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer\u2019s disease. PloS one 7, e52056, https:\/\/doi.org\/10.1371\/journal.pone.0052056 (2012).","journal-title":"PloS one"},{"key":"22979_CR64","doi-asserted-by":"publisher","first-page":"11820","DOI":"10.1523\/JNEUROSCI.0875-12.2012","volume":"32","author":"B Oules","year":"2012","unstructured":"Oules, B. et al. Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 32, 11820\u201311834, https:\/\/doi.org\/10.1523\/JNEUROSCI.0875-12.2012 (2012).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR65","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.neulet.2012.04.008","volume":"516","author":"J Peng","year":"2012","unstructured":"Peng, J. et al. Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Neurosci Lett 516, 274\u2013279, https:\/\/doi.org\/10.1016\/j.neulet.2012.04.008 (2012).","journal-title":"Neurosci Lett"},{"key":"22979_CR66","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1523\/JNEUROSCI.4367-12.2013","volume":"33","author":"A Demuro","year":"2013","unstructured":"Demuro, A. & Parker, I. Cytotoxicity of intracellular abeta42 amyloid oligomers involves Ca2+ release from the endoplasmic reticulum by stimulated production of inositol trisphosphate. The Journal of neuroscience: the official journal of the Society for Neuroscience 33, 3824\u20133833, https:\/\/doi.org\/10.1523\/JNEUROSCI.4367-12.2013 (2013).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR67","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.neuron.2010.04.029","volume":"66","author":"M Renner","year":"2010","unstructured":"Renner, M. et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739\u2013754, https:\/\/doi.org\/10.1016\/j.neuron.2010.04.029 (2010).","journal-title":"Neuron"},{"key":"22979_CR68","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta, P. D. et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100\u2013105 (2000).","journal-title":"Arch Neurol"},{"key":"22979_CR69","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1212\/WNL.59.3.398","volume":"59","author":"A Delacourte","year":"2002","unstructured":"Delacourte, A. et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer\u2019s disease. Neurology 59, 398\u2013407 (2002).","journal-title":"Neurology"},{"key":"22979_CR70","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1096\/fj.09-150359","volume":"24","author":"H Fukumoto","year":"2010","unstructured":"Fukumoto, H. et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24, 2716\u20132726, https:\/\/doi.org\/10.1096\/fj.09-150359 (2010).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"22979_CR71","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698\u2013712, https:\/\/doi.org\/10.1038\/nrd3505 (2011).","journal-title":"Nat Rev Drug Discov"},{"key":"22979_CR72","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.brainres.2012.02.041","volume":"1450","author":"JM McDonald","year":"2012","unstructured":"McDonald, J. M., Cairns, N. J., Taylor-Reinwald, L., Holtzman, D. & Walsh, D. M. The levels of water-soluble and triton-soluble Abeta are increased in Alzheimer\u2019s disease brain. Brain Res 1450, 138\u2013147, https:\/\/doi.org\/10.1016\/j.brainres.2012.02.041 (2012).","journal-title":"Brain Res"},{"key":"22979_CR73","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"LF Lue","year":"1999","unstructured":"Lue, L. F. et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease. Am J Pathol 155, 853\u2013862 (1999).","journal-title":"Am J Pathol"},{"key":"22979_CR74","doi-asserted-by":"publisher","first-page":"e66381","DOI":"10.1371\/journal.pone.0066381","volume":"8","author":"M Holtta","year":"2013","unstructured":"Holtta, M. et al. Evaluating amyloid-beta oligomers in cerebrospinal fluid as a biomarker for Alzheimer\u2019s disease. PloS one 8, e66381, https:\/\/doi.org\/10.1371\/journal.pone.0066381 (2013).","journal-title":"PloS one"},{"key":"22979_CR75","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/nprot.2013.078","volume":"8","author":"KR Kay","year":"2013","unstructured":"Kay, K. R. et al. Studying synapses in human brain with array tomography and electron microscopy. Nature protocols 8, 1366\u20131380, https:\/\/doi.org\/10.1038\/nprot.2013.078 (2013).","journal-title":"Nature protocols"},{"key":"22979_CR76","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1109\/83.650848","volume":"7","author":"P Thevenaz","year":"1998","unstructured":"Thevenaz, P., Ruttimann, U. E. & Unser, M. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process 7, 27\u201341, https:\/\/doi.org\/10.1109\/83.650848 (1998).","journal-title":"IEEE Trans Image Process"},{"key":"22979_CR77","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1096\/fj.10-164624","volume":"25","author":"KM Danzer","year":"2011","unstructured":"Danzer, K. M. et al. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 25, 326\u2013336, https:\/\/doi.org\/10.1096\/fj.10-164624 (2011).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"22979_CR78","first-page":"349","volume":"299","author":"J Skoch","year":"2005","unstructured":"Skoch, J., Hickey, G. A., Kajdasz, S. T., Hyman, B. T. & Bacskai, B. J. In vivo imaging of amyloid-beta deposits in mouse brain with multiphoton microscopy. Methods in molecular biology 299, 349\u2013363 (2005).","journal-title":"Methods in molecular biology"},{"key":"22979_CR79","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1523\/JNEUROSCI.1879-05.2005","volume":"25","author":"TL Spires","year":"2005","unstructured":"Spires, T. L. et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. The Journal of neuroscience: the official journal of the Society for Neuroscience 25, 7278\u20137287, https:\/\/doi.org\/10.1523\/JNEUROSCI.1879-05.2005 (2005).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"22979_CR80","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1097\/00004647-200209000-00001","volume":"22","author":"BJ Bacskai","year":"2002","unstructured":"Bacskai, B. J., Klunk, W. E., Mathis, C. A. & Hyman, B. T. Imaging amyloid-beta deposits in vivo. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 22, 1035\u20131041, https:\/\/doi.org\/10.1097\/00004647-200209000-00001 (2002).","journal-title":"Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism"},{"key":"22979_CR81","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/jnen\/61.9.797","volume":"61","author":"WE Klunk","year":"2002","unstructured":"Klunk, W. E. et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. Journal of neuropathology and experimental neurology 61, 797\u2013805 (2002).","journal-title":"Journal of neuropathology and experimental neurology"},{"key":"22979_CR82","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1016\/S0021-9258(19)83641-4","volume":"260","author":"G Grynkiewicz","year":"1985","unstructured":"Grynkiewicz, G., Poenie, M. & Tsien, R. Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260, 3440\u20133450 (1985).","journal-title":"J Biol Chem"},{"key":"22979_CR83","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/nprot.2006.172","volume":"1","author":"AE Palmer","year":"2006","unstructured":"Palmer, A. E. & Tsien, R. Y. Measuring calcium signaling using genetically targetable fluorescent indicators. Nature protocols 1, 1057\u20131065, https:\/\/doi.org\/10.1038\/nprot.2006.172 (2006).","journal-title":"Nature protocols"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22979-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22979-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22979-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T03:26:14Z","timestamp":1671593174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22979-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["22979"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-22979-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"18 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J. is a consultant of Acumen Pharmaceuticals, Inc. and owns stock in the company; G.A.K. and F.H. are members of the scientific advisory board of Acumen Pharmaceuticals, Inc. and own stock in the company. All other authors declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4634"}}